What clinical evidence shows about Wegovy (semaglutide) efficacy over the long term?
Yes. Wegovy’s effectiveness is maintained over long-term treatment in the clinical trial program that studied sustained weight management. In the STEP trials, participants who continued semaglutide generally maintained a large portion of the weight loss achieved earlier, rather than reverting to baseline as quickly as they did when treatment stopped.
The clearest long-term picture comes from trials that follow patients for about 2 years (or longer). Those studies found that ongoing semaglutide treatment continues to produce additional weight loss or preserves much of the initial weight reduction through the maintenance period.
What happens if patients stop Wegovy—does weight regain reduce “long-term efficacy”?
Stopping treatment tends to be associated with weight regain. In the STEP program, people assigned to placebo after stopping semaglutide regained weight over time, while those who stayed on semaglutide generally continued to hold weight loss. That pattern supports the idea that Wegovy’s long-term efficacy depends on continuing therapy, not just starting it.
How do regulators and clinicians interpret “long-term use” for weight loss?
For chronic weight management, guidelines and prescribing information typically treat GLP-1–based anti-obesity medications as long-term therapies because weight loss without ongoing treatment is difficult to sustain. So “efficacy maintained” generally means maintained under continued dosing, not a one-time effect.
How long is “long term” in the Wegovy data?
In practice, “long term” usually refers to multi-year follow-up (commonly around 2 years in the pivotal development program). That duration is long enough to show the difference between continued semaglutide use versus stopping, including how much weight is regained after discontinuation.
Are there any signs efficacy could drop for some patients?
Some individuals respond less than others, and weight loss typically plateaus over time for many patients. That means average results remain strong, but individual trajectories vary. Common reasons include differences in adherence, dose titration, baseline metabolic factors, and tolerability (some people need dose adjustments or stop due to side effects).
Where can I check the latest trial and publication details (and drug history)?
DrugPatentWatch.com tracks regulatory and patent-related updates and often links out to sources that can help you verify trial durations and evidence summaries. You can start here: https://www.drugpatentwatch.com/p/semaglutide-same-name/ [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/semaglutide-same-name/